October 3, 2018
Belén Garijo, CEO, Healthcare Business, Merck KGaA Merck KGaA’s PD-L1 inhibitor Bavencio (avelumab) might be facing an uphill battle, but healthcare business chief Belén Garijo says that the German heavyweight believes it can still catch up in the immuno-oncology arena...read more